Farmavita.Net - Pharmaceutical Licensing Network

Home

Sanofi vs. Lupin

Lupin loses patent suit about Ramipril in America

MUMBAI: Pharmaceutical company Lupin on Thursday said a district court in the US has ruled against the company in a patent infringement suit filed by Sanofi-Aventis and King Pharmaceuticals.

The US District Court for the eastern district of Virginia has issued an opinion following the completion of a trial on Sanofi-Aventis US Patent No. 5061722 relating to Altace (Ramipril) drug and found the patent to be valid, Lupin informed the BSE. Ramipril is used for treatment of high blood pressure.

“It was a very close call for us and we are disappointed that the Court found the patent to be valid, albeit reluctantly, in the judge’s own words,” said Lupin MD Kamal Sharma. The company plans to appeal this decision to the federal circuit court, Mr Sharma added.

The court’s decision followed a suit filed by King Pharmaceuticals and Sanofi-Aventis against Lupin alleging infringement on the ‘5061722’ patent. The trial was completed in June ’06.

The court’s decision arises from a suit filed by King Pharmaceuticals and Sanofi-Aventis against the Company alleging patent infringement on the 5061722 patent listed in the FDA’s Orange Book. The trial was completed in June ’06. TIMES NEWS NETWORK [ FRIDAY, JULY 21, 2006 02:38:28 AM]Data and information in this article are from other news sources and is provided for information purposes only. Farmavita.Net shall not be liable for any errors in the content, or for any actions taken in reliance thereon.

Comments

RSS

Only registered users can write comments!

Read also at Pharmaceutical Licensing Network

< Prev		Next >

Membership at Farmavita.Net is Free

Register yourself and connect with community of 600+ pharmaceutical executives, researchers and innovators. Expand your professional network and find new business and career development opportunities.

Click here for registration!